DLL3-Targeted Therapies Market Forecast To 2036 Highlights Expanding Opportunities In Small Cell Lung Cancer And Neuroendocrine Carcinomas
Dublin, Sept. 14, 2026 (GLOBE NEWSWIRE) -- "Delta-Like Ligand 3 (DLL3)-Targeted Therapies - Target Population, Competitive Landscape, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
The "Delta-like Ligand 3 (DLL3)-Targeted Therapies - Target Population, Competitive Landscape, and Market Forecast - 2036" report provides a comprehensive analysis of the evolving DLL3-targeted therapies market across the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Covering 2022-2036, the report evaluates epidemiology, treatment practices, approved and emerging therapies, market size, drug uptake, competitive dynamics, reimbursement, and commercial opportunities.
Key Market Highlights
- DLL3 is overexpressed in small cell lung cancer (SCLC) and several neuroendocrine carcinomas and tumors, with elevated expression associated with tumor progression, metastasis, treatment resistance, and poor prognosis. The US Food and Drug Administration's May 2024 accelerated approval of Amgen's IMDELLTRA (tarlatamab-dlle) established the first approved DLL3-targeted therapy for adults with extensive-stage small cell lung cancer (ES-SCLC) progressing on or after platinum-based chemotherapy. The DLL3-targeted therapies pipeline includes bispecific and trispecific T-cell engagers, antibody-drug conjugates, CAR-T cell therapies, antibody radionuclide conjugates, and other targeted platforms. Leading pipeline candidates include peluntamig, gocatamig (MK-6070/HPN328-4001/DS3280), LB2102, 225Ac-ABD147, obrixtamig (BI 764532), ALPS12/RG6524, and zocilurtatug pelitecan (ZL-1310). Small cell lung cancer is expected to remain the primary commercial segment in the near term, while future growth may be supported by development in large cell neuroendocrine carcinoma, neuroendocrine prostate cancer, and extrapulmonary neuroendocrine carcinomas.
DLL3-Targeted Therapies Market Overview
DLL3 displays low expression in most normal tissues but is frequently overexpressed and abnormally localized on the surface of malignant cells. Cell-surface expression has been reported in up to 85% of human SCLC tumors, supporting DLL3 as a tumor-selective therapeutic target. DLL3 is also expressed in subsets of pulmonary large cell neuroendocrine carcinoma, gastroenteropancreatic neuroendocrine malignancies, bladder cancer, prostate cancer, and cervical neuroendocrine carcinoma.
The market includes multiple therapeutic approaches designed to exploit this expression profile. Clinical development is currently concentrated in early-stage programs, although increasing regulatory activity, strategic partnerships, and registration-enabling studies indicate growing confidence in the target's commercial potential.
Epidemiology and Target Population
The report segments the DLL3-targeted patient population by total cases in selected indications, eligible patients, DLL3-expressing cases, and treated cases across the seven major markets. SCLC accounts for the largest target population. In 2025, the United States recorded nearly 37,000 incident SCLC cases, including approximately 31,500 DLL3-positive cases.
Neuroendocrine prostate cancer represents another important target segment, with the EU4 and the United Kingdom reporting nearly 6,500 DLL3-expressing cases in 2025. Large cell neuroendocrine carcinoma forms a smaller but clinically relevant population; Japan accounted for approximately 2,000 DLL3-expressing locally advanced or metastatic cases in 2025.
Approved and Emerging DLL3-Targeted Therapies
IMDELLTRA is a DLL3-directed bispecific T-cell engager that binds DLL3 on tumor cells and CD3 on T cells. Its 2024 US approval marked a major milestone for the DLL3-targeted therapies market and introduced an important treatment option for previously treated ES-SCLC. The therapy subsequently secured approvals in additional markets, strengthening its early commercial position. In 2025, IMDELLTRA's estimated market value approached USD 400 million across the seven major markets.
Gocatamig (MK-6070), developed through the Merck and Daiichi Sankyo collaboration, is an investigational DLL3-directed trispecific T-cell engager under Phase I/II evaluation as monotherapy in DLL3-expressing advanced cancers and in combination with atezolizumab in SCLC. The FDA granted orphan drug designation for SCLC in March 2022.
Obrixtamig (BI 764532), developed by Boehringer Ingelheim and originating from a collaboration with Oxford BioTherapeutics, is under investigation in relapsed or refractory ES-SCLC and other neuroendocrine carcinomas. The program has received FDA fast track designations for multiple neuroendocrine cancer settings and orphan drug designation for SCLC.
Zocilurtatug pelitecan (ZL-1310), from Zai Lab and MedLink Therapeutics, is a DLL3-targeting antibody-drug conjugate in development for SCLC and extrapulmonary neuroendocrine carcinomas. In May 2026, the FDA granted fast track designation for previously treated extrapulmonary neuroendocrine carcinomas. Zai Lab expects registration-enabling development across second-line or later SCLC, first-line SCLC, and extrapulmonary neuroendocrine carcinomas.
Recent DLL3 Market Developments
- In June 2026, the European Commission approved Amgen's IMDYLLTRA as monotherapy for adults with ES-SCLC progressing after first-line platinum-based chemotherapy, supported by Phase III DeLLphi-304 results. In May 2026, Merck reaffirmed confidence in the development and commercial potential of gocatamig and its partnered oncology portfolio. In May 2026, ZL-1310 received FDA fast track designation for previously treated extrapulmonary neuroendocrine carcinomas. Strategic collaborations, licensing agreements, acquisitions, and manufacturing investments continue to shape competition within the DLL3-targeted therapies pipeline.
Market Outlook and Commercial Opportunity
The DLL3-targeted therapies market is expected to expand gradually as approved products gain adoption and emerging candidates advance through clinical development. Near-term revenue will remain strongly linked to SCLC, particularly ES-SCLC, because most pipeline assets are initially targeting this indication. Broader market diversification is anticipated following later-stage data from studies in large cell neuroendocrine carcinoma, neuroendocrine prostate cancer, and extrapulmonary neuroendocrine carcinomas.
The report assesses therapy-specific market share, forecast assumptions, pricing variation, reimbursement, country-level accessibility, treatment costs, and patient assistance programs. It also examines market access decisions across public and private healthcare systems, including Medicare, Medicaid, pharmacy benefit managers, and health technology assessment bodies.
Report Scope and Strategic Insights
- Historical and forecast DLL3-targeted therapies market size from 2022 to 2036. Country-level epidemiology and eligible patient populations across the seven major markets. Profiles of approved, late-stage, mid-stage, and early-stage DLL3-targeted therapies. Clinical trial activity, regulatory designations, collaborations, licensing, patents, and recent corporate developments. Drug uptake forecasts, treatment algorithms, competitive benchmarking, and indication-level opportunity analysis. Market access, reimbursement, affordability, and geographic accessibility assessments. SWOT analysis covering patient burden, diagnosis, awareness, competition, cost-effectiveness, and unmet medical needs. Insights from key opinion leaders across major oncology centers in the United States, Europe, the United Kingdom, and Japan.
Reasons to Buy
The report supports pharmaceutical companies, investors, healthcare organizations, and strategic decision-makers seeking to understand the DLL3-targeted therapies competitive landscape. It identifies high-growth indications, emerging market entrants, therapy adoption trends, reimbursement barriers, unmet needs, and commercialization opportunities through 2036.
By combining patient population analysis, real-world treatment trends, product-level forecasts, expert insights, and competitive intelligence, the report enables stakeholders to strengthen clinical development, market access, portfolio planning, and product launch strategies within the rapidly advancing DLL3-targeted oncology market.
Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Executive Summary of Delta-like Ligand 3 (DLL3)-targeted Therapies
4. Key Events
5. Epidemiology Market Forecast Methodology of Delta-like Ligand 3 (DLL3)-targeted Therapies
6. Delta-like Ligand 3 (DLL3)-targeted Therapies Market Overview at a Glance in the 7MM
6.1. Market Share (%) Distribution by Therapies in 2025
6.2. Market Share (%) Distribution by Therapies in 2036
6.3. Market Share (%) Distribution by Indications in 2025
6.4. Market Share (%) Distribution by Indications in 2036
7. Delta-like Ligand 3 (DLL3)-targeted Therapies: Background and Overview
7.1. Introduction
7.2. The Potential of Delta-like Ligand 3 (DLL3)-targeted Therapies in Different Indications
7.3. Clinical Applications of Delta-like Ligand 3 (DLL3)-targeted Therapies
8. Target Patient Pool of Delta-like Ligand 3 (DLL3)-targeted Therapies
8.1. Assumptions and Rationale
8.2. Key Findings
8.3. Total Cases of Selected Indication for Delta-like Ligand 3 (DLL3)-targeted Therapies in the 7MM
8.4. Total Eligible Patient Pool of Selected Indication for Delta-like Ligand 3 (DLL3)-targeted Therapies in the 7MM
8.5. Total Treatable Cases in Selected Indication for Delta-like Ligand 3 (DLL3)-targeted Therapies in the 7MM
9. Marketed Delta-like Ligand 3 (DLL3)-targeted Therapies
9.1. Key Competitors
9.2. IMDELLTRA (tarlatamab-dlle): Amgen
9.2.1. Product Description
9.2.2. Regulatory Milestones
9.2.3. Other Developmental Activities
9.2.4. Clinical Development
9.2.5. Safety and Efficacy
9.2.6. Analyst View
10. Emerging Delta-like Ligand 3 (DLL3)-targeted Therapies
10.1. Key Competitors
10.2. Peluntamig (PT217): Phanes Therapeutics
10.2.1. Product Description
10.2.2. Other Developmental Activities
10.2.3. Clinical Development
10.2.4. Safety and Efficacy
10.2.5. Analyst Views
10.3. MK-6070/ HPN328-4001/ DS3280: Merck/ Daiichi Sankyo
10.3.1. Product Description
10.3.2. Other Developmental Activities
10.3.3. Clinical Development
10.3.4. Safety and Efficacy
10.3.5. Analyst Views
List to be continued in the report
11. Delta-like Ligand 3 (DLL3)-targeted Therapies: Seven Major Market Analysis
11.1. Key Findings
11.2. Market Outlook of Delta-like Ligand 3 (DLL3)-targeted Therapies
11.3. Conjoint Analysis of Delta-like Ligand 3 (DLL3)-targeted Therapies
11.4. Key Market Forecast Assumptions of Delta-like Ligand 3 (DLL3)-targeted Therapies
11.4.1. Cost Assumptions and Rebates
11.4.2. Pricing Trends
11.4.3. Analogue Assessment
11.4.4. Launch Year and Therapy Uptakes
11.5. Total Market Sizes of Delta-like Ligand 3 (DLL3)-targeted Therapies by Indications in the 7MM
11.6. The United States
11.6.1. Total Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies in the United States
11.6.2. Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies by Indication in the United States
11.6.3. Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies by Therapies in the United States
11.7. EU4 and the UK
11.7.1. Total Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies in EU4 and the UK
11.7.2. Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies by Indications in EU4 and the UK
11.7.3. Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies by Therapies in EU4 and the UK
11.8. Japan
11.8.1. Total Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies Inhibitors in Japan
11.8.2. Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies by Indications in Japan
11.8.3. Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies by Therapies in Japan
12. SWOT Analysis of Delta-like Ligand 3 (DLL3)-targeted Therapies
13. KOL Views of Delta-like Ligand 3 (DLL3)-targeted Therapies
14. Unmet Needs of Delta-like Ligand 3 (DLL3)-targeted Therapies
15. Market Access and Reimbursement of Delta-like Ligand 3 (DLL3)-targeted Therapies
16. Appendix
16.1. Bibliography
16.2. Report Methodology
17. Analyst's Capabilities
18. Disclaimer
19. About the Publisher
List of Tables
Table 1: Target Population in the 7MM (2022-2036)
Table 2: Marketed Drug Key cross
Table 3: Product 1, Clinical Trial Description, 2025
Table 4: Product 2, Clinical Trial Description, 2025
Table 5: Emerging Drug Key cross
Table 6: Product 1, Clinical Trial Description, 2025
Table 7: Product 2, Clinical Trial Description, 2025
Table 8: Total Delta-like Ligand 3 (DLL3)-targeted Therapies Market Size in the 7MM (2022-2036)
Table 9: Delta-like Ligand 3 (DLL3)-targeted Therapies Market Size by Therapies in the 7MM (2022-2036)
Table 10: Delta-like Ligand 3 (DLL3)-targeted Therapies Market Size by Indication in the 7MM (2022-2036)
Table 11: Total Delta-like Ligand 3 (DLL3)-targeted Therapies Market Size in the United States (2022-2036)
Table 12: Delta-like Ligand 3 (DLL3)-targeted Therapies Market Size by Therapies in the United States (2022-2036)
Table 13: Total Delta-like Ligand 3 (DLL3)-targeted Therapies Market Size in EU4 and the UK (2022-2036)
Table 14: Delta-like Ligand 3 (DLL3)-targeted Therapies Market Size by Therapies in EU4 and the UK (2022-2036)
Table 15: Total Delta-like Ligand 3 (DLL3)-targeted Therapies Market Size in Japan (2022-2036)
Table 16: Delta-like Ligand 3 (DLL3)-targeted Therapies Market Size by Therapies in Japan (2022-2036)
List of Figures
Figure 1: Target Population in the 7MM (2022-2036)
Figure 2: Total Delta-like Ligand 3 (DLL3)-targeted Therapies Market Size in the 7MM (2022-2036)
Figure 3: Delta-like Ligand 3 (DLL3)-targeted Therapies Market Size by Therapies in the 7MM (2022-2036)
Figure 4: Delta-like Ligand 3 (DLL3)-targeted Therapies Market Size by Indication in the 7MM (2022-2036)
Figure 5: Total Delta-like Ligand 3 (DLL3)-targeted Therapies Market Size in the United States (2022-2036)
Figure 6: Delta-like Ligand 3 (DLL3)-targeted Therapies Market Size by Therapies in the United States (2022-2036)
Figure 7: Total Delta-like Ligand 3 (DLL3)-targeted Therapies Market Size in EU4 and the UK (2022-2036)
Figure 8: Delta-like Ligand 3 (DLL3)-targeted Therapies Market Size by Therapies in EU4 and the UK (2022-2036)
Figure 9: Total Delta-like Ligand 3 (DLL3)-targeted Therapies Market Size in Japan (2022-2036)
Figure 10: Delta-like Ligand 3 (DLL3)-targeted Therapies Market Size by Therapies in Japan (2022-2036)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Phanes Therapeutics Merck Daiichi Sankyo
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment